Publications by authors named "Anna Tisza"

Aims: Pleural mesothelioma (PM) is a highly aggressive thoracic tumour with poor prognosis. Although reduced tissue drug accumulation is one of the key features of platinum (Pt) resistance, little is known about Pt distribution in human PM.

Methods: We assessed Pt levels of blood samples and surgically resected specimens from 25 PM patients who had received neoadjuvant Pt-based chemotherapy (CHT).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how malignant pleural mesothelioma (MPM) forms blood vessels and how it resists anti-angiogenic treatments, using human MPM cell lines implanted in the pleura.
  • Results showed that P31 cells were more mobile and invasive than SPC111 cells, and that P31 encouraged blood vessel growth while SPC111's growth pattern inhibited this.
  • Two distinct growth patterns of MPM were identified: a more invasive pattern co-opting existing blood vessels and a desmoplastic pattern that creates a dense tissue barrier, impacting overall vascularization.
View Article and Find Full Text PDF

Objectives: Circulating levels of activin A (ActA) and follistatin (FST) have been investigated in various disorders including malignancies. However, to date, their diagnostic and prognostic relevance is largely unknown in small cell lung cancer (SCLC). Our aim was to evaluate circulating ActA and FST levels as potential biomarkers in this devastating disease.

View Article and Find Full Text PDF

Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, sorafenib, sunitinib, vatalanib) with their intratumoral distribution data obtained by matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI). In the first mouse model, only sunitinib exhibited broad-spectrum antivascular and antitumor activities by simultaneously suppressing vascular endothelial growth factor receptor-2 (VEGFR2) and desmin expression, and by increasing intratumoral hypoxia and inhibiting both tumor growth and vascularisation significantly.

View Article and Find Full Text PDF